Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy
Shaoxing Guan(Sun Yat-sen University), Jinzhang Chen(Nanfang Hospital), Guosheng Yuan(Nanfang Hospital), Yongru Chen(Nanfang Hospital), Min Huang(East China University of Technology), Jian‐Hong Fang(University of Electronic Science and Technology of China), Rui Li(Hebei University of Engineering), Tu Xian(Sun Yat-sen University), Huichang Bi(Southern Medical University), Sumyuet Chan(Sun Yat-sen University), Gengyi Zhang(Sun Yat-sen University)
Cited by 2
Related Papers
Temporal trend and attributable risk factors of stroke burden in China, 1990–2019: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2021|899
Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion
|New England Journal of Medicine|2022|665
Current trends in drug metabolism and pharmacokinetics
|Acta Pharmaceutica Sinica B|2019|391
Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma
|International Journal of Clinical Practice|2008|226
Spatial and temporal variation of particulate matter and gaseous pollutants in China during 2014–2016
|Atmospheric Environment|2017|174